GSK-209762/149 (MeMuRu-149)



Phase IV, single-blind, randomised, multicenter study to evaluate immediate post-vaccination pain, reactogenicity and tolerance of GSK Biologicals' Measles-Mumps-Rubella vaccine (Priorix) administered as a second dose compared to Aventis-Pasteur-MSDs Measles-Mumps-Rubella vaccine (ROR Vax)
Measles, Mumps, Rubella Vaccine
209762/149 (MeMuRu-149)
Measles; Mumps; Rubella
Phase 4
 
An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2015